7Baggers
 v2y corporation ltd expands into renewable energy and commodities  The Globe and Mail Sun, 16 Nov 2025 11:18:59 GMT
 Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO)  Seeking Alpha Thu, 06 Nov 2025 08:00:00 GMT
 Lexeo Therapeutics, Inc. SEC 10-Q Report  TradingView Wed, 05 Nov 2025 12:43:00 GMT
 Lexeo Therapeutics reports Q3 EPS (33c), consensus (44c)  TipRanks Wed, 05 Nov 2025 08:00:00 GMT
 ra capital management, l.p. acquires 5 million shares in lexeo t  GuruFocus Fri, 31 Oct 2025 21:11:15 GMT
 published on: 2025-10-27 17:31:25  newser.com Mon, 27 Oct 2025 22:31:25 GMT

Lexeo Therapeutics, Inc.
(NASDAQ:LXEO) 

LXEO stock logo

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene t...

Founded: 2017
IPO Price: $11 (Nov 13, 2023)
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends